Suchergebnisse - "Jones, John R"

PubPharm (12)

1

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial

enthalten in: EClinicalMedicine | 2023

von Jones, J. | Cairns, D. | Menzies, T. | +15

2

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages : results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial

enthalten in: British journal of haematology | 2023

von Jenner, M. | Pawlyn, C. | Davies, F. | +16

3

Second primary malignancies in patients with haematological cancers treated with lenalidomide : a systematic review and meta-analysis

enthalten in: The Lancet. Haematology | 2022

von Saleem, K. | Franz, J. | Klem, M. | +5

CommentIn: Lancet Haematol. 2022 Dec;9(12):e868-e869. - PMID 36457218

4

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma : Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von de Tute, R. | Pawlyn, C. | Cairns, D. | +14

CommentIn: J Clin Oncol. 2022 Sep 1;40(25):2863-2866. - PMID 35772041

5

Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation

enthalten in: Expert opinion on drug safety | 2021

von Jones, J. | Pawlyn, C. | Jackson, G.

6

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

enthalten in: Haematologica | 2021

von Jackson, G. | Davies, F. | Pawlyn, C. | +21

7

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma : results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial

enthalten in: British journal of haematology | 2021

von Jackson, G. | Pawlyn, C. | Cairns, D. | +21

8

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+) : Interim analysis of an open-label randomised controlled trial

enthalten in: PLoS medicine | 2021

von Jackson, G. | Pawlyn, C. | Cairns, D. | +21

9

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

enthalten in: Blood | 2020

von Craig, Z. | Cook, G. | Pawlyn, C. | +13

CommentIn: Blood. 2020 Aug 27;136(9):1019-1021. - PMID 32853375

10

Clonal evolution in myeloma : the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients

enthalten in: Haematologica | 2019

von Jones, J. | Weinhold, N. | Ashby, C. | +20

CommentIn: Haematologica. 2019 Jul;104(7):1292-1293. - PMID 31257204